Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical…
Biotechnology
US, Pittsburgh [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -28.76 | 12.66 | 17.76 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 76.63 | -17.62 | -75.40 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 2.19 | 28.25 | 27.64 | |
| Cash | 0.69 | 19.02 | 18.89 | |
| Capex | 32.09 | -0.04 | -0.07 | |
| Free Cash Flow | 60.40 | 0.52 | -0.32 | |
| Revenue | 6.89 | 1.60 | 1.50 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 5.63 | 0.95 | 0.90 | |
| Operating Margin | 98.38 | -0.15 | 0.07 | |
| ROA | -89.72 | < 0.005 | 0.01 | |
| ROE | -89.55 | < 0.005 | 0.01 | |
| ROIC | 979.40 | 0.04 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of KRYS is permitted for members.
5
Growth
The "Growth Entry" for the Focus of KRYS is permitted for members.
6
Leverage & Liquidity